Medable’s Capabilities Cut Trial Technology Deployment Timelines By 50%
Medable Wins 2023 Prix Galien Award for Best Digital Health Solution
Trial software company Medable will partner with health data provider Pluto Health to simplify and speed up the patient recruitment and retention process.
Medable Inc., a technology provider for patient-centric clinical trials, and the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) announced a comprehensive toolkit for Institutional Review Boards (IRBs)/Ethics Committees (ECs) to standardize decentralized clinical trial (DCT) ethics review.
PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the leading technology provider for patient-centric clinical trials, and the Multi-Regional Clinical Trials Center of Brigham and Women’s Hospital and Harvard (MRCT Center) announce a comprehensive toolkit for Institutional Review Boards (IRBs)/Ethics Committees (ECs) to standardize decentralized clinical trial (DCT) ethics review. The first-of-its-kind toolkit provides a common framework, tools, and best practices for uniform ethical review and approval and provides a roadmap for the ethical conduct of DCTs. Ultimately, such standardization will simplify, streamline, and speed the IRB/EC process – a key step towards more efficient, patient-centered research execution.
PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the industry-leading technology platform for patient-centered clinical trials, today announced a partnership with non-profit Every Cure, which officially launched in September in partnership with the Clinton Global Initiative to scale up an innovative “drug repurposing” research approach to identify treatments for rare diseases.
CRO Syneos Health and Medable have extended their partnership that was formed in the spring of 2021 to boost decentralized clinical trials and improve patient diversity.
Syneos Health Extends Partnership with Medable
Medable has launched a completely enabled SaaS electronic consent management solution, Total Consent, for all decentralised and hybrid clinical trials in over 120 locations globally.
PALO ALTO, Calif.--(BUSINESS WIRE)--Medable Inc., the industry-leading technology platform for patient-centered clinical trials, today announced a new patient-first oncology offering that enables life sciences companies to improve patient access, enrollment, and retention in cancer trials. Medable’s new offering is an end-to-end suite that includes pre-built and validated DCT applications such as Total Consent and Televisit, an extensive eCOA oncology library, and protocol design consulting – with a single point of entry for patients, sites and sponsors.